A Phase 2 clinical trial for CT-868 , a once-daily dual GLP-1/GIP receptor agonist, in adult subjects who are overweight or obese with T1D, has been initiated by Carmot Therapeutics Inc
10.2337/ds20-0072
Quick Answer: Back pain is not a recognized direct side effect of GLP-1 receptor agonists according to FDA prescribing information and clinical trial data
That finding changed how topiramate, sold under the brand name Topamax, is used today
Miguel CA, Noya-Riob MV, Mazzone GL, Villar MJ, Coronel MF (2021) Antioxidant, anti-inflammatory and neuroprotective actions of resveratrol after experimental nervous system insults
And while some of these ingredients have modest evidence for metabolic benefits when taken orally, the evidence for skin absorption is essentially nonexistent